We report a case of ovarian hyperstimulation syndrome associated with fetal trisomy 21. A primigravida presented at 17 1/7 weeks of gestation with abdominal pain because of enlarged ovaries. Multiple fetal abnormalities were seen on pregnancy ultrasound. Fetal trisomy 21 was diagnosed by amniocentesis. The patient's human chorionic gonadotropin level was markedly elevated, as often occurs with fetal trisomy 21, and was likely associated with the ovarian hyperstimulation. Ovarian hyperstimulation syndrome associated with fetal aneuploidy has not been previously described. Journal of Perinatology (2009) 29, 388-390; doi:10.1038/jp.2008 Keywords: aneuploidy; trisomy 21; ovarian hyperstimulation
Case
The ovarian hyperstimulation syndrome (OHSS) refers to a combination of ovarian enlargement because of multiple ovarian cysts and an acute fluid shift out of the intravascular space. Most cases of OHSS are associated with the use of exogenously administered gonadotropins and occasionally clomiphene citrate. We discuss a case of mild OHSS resulting from a singleton gestation conceived after spontaneous ovulation. The pregnancy was complicated by fetal trisomy 21; serum human chorionic gonadotropin (hCG) levels were presumably associated with the OHSS.
A 35-year-old Asian primigravida who conceived spontaneously presented to the emergency room at 17 1/7 weeks of gestation with abdominal pain of 2 days' duration. She denied fevers, nausea, vomiting, diarrhea or other complaints. Her prenatal course had been unremarkable until that point. She had not undergone serum screening for her advanced maternal age status. She had no notable medical, surgical or gynecologic history. She used no medications and had no drug allergies. She did not smoke, drink alcohol or use drugs. Vital signs were stable. On physical exam, the abdomen was tender in both lower quadrants, but without rebound or guarding. Bowel sounds were normal. On pelvic exam, the cervix was closed and nontender. No discharge or bleeding were appreciated.
On laboratory testing, complete blood count and electrolytes were within normal limits. hCG level was 430 525 IU l À1 . Pelvic ultrasound showed enlarged maternal ovaries. The right ovary measured 6.2 Â 4.9 Â 4.6 cm and contained multiple cysts, the largest measuring 2.8 cm. The left ovary measured 3.8 Â 4.5 Â 3.5 cm, also with multiple cysts, the largest measuring 1.8 cm. Pregnancy ultrasound showed fetal biometry consistent with 17 1/7 weeks of gestation. A 1.6 cm cystic hygroma was seen, along with hydrops. Scalp edema and ascites were visible. The amniotic fluid volume was normal. The patient was discharged home from the emergency room with prescriptions for pain medication.
The next day, the patient presented for counseling regarding the fetal ultrasound. She elected to undergo amniocentesis; the karyotype indicated fetal trisomy 21. Pregnancy options were discussed; the patient opted for expectant management. At 18 weeks, ultrasound showed a fetal pericardial effusion. At 19 weeks, severe oligohydramnios developed. The ovaries remained enlarged, with the right ovary measuring 7 cm in diameter and the left ovary measuring 8 cm. At 21 weeks, the patient decided to have a pregnancy termination by dilation and evacuation. The day she presented for the procedure, a fetal demise was diagnosed. The dilation and evacuation was uneventful, as was the patient's postprocedure course. Since then, the patient has had an uncomplicated pregnancy resulting in a full term delivery. In her subsequent pregnancy, the ovaries appeared unremarkable on ultrasounds carried out in the first and second trimesters, with no evidence of OHSS.
Discussion
OHSS is classified according to the severity of symptoms and laboratory findings. Grade I OHSS is characterized by bilateral ovarian enlargement up to 5 Â 5 cm, with mild follicular and corpus luteum cysts. Serum estradiol levels are usually elevated to greater than 1500 pg ml À1 , and serum progesterone levels are elevated to greater than 30 ng ml À1 . Grade II OHSS consists of ovaries enlarged up to 12 Â 12 cm, with abdominal discomfort. In grade III disease, the ovaries are enlarged to greater than 12 Â 12 cm. Maternal ascites, pleural or pericardial effusions, electrolyte imbalance and hypovolemia can develop. Hemoconcentration, increased blood viscosity, thromboemboli and disseminated intravascular coagulopathy can also occur. 1 This patient had grade I OHSS initially, with progression to grade II based on ovarian size.
In spontaneous ovulatory cycles, hypothalamic-pituitaryovarian feedback mechanisms limit follicular development to a small number of early antral follicles. A single leading follicle usually ovulates in response to the midcycle surge in luteinizing hormone (LH). When normal feedback mechanisms are interrupted (for instance, in the presence of high levels of exogenous or endogenous gonadotropins), a large number of antral follicles are recruited. Multiple follicles are sustained as leading follicles capable of luteinization or ovulation. Ovarian hyperstimulation occurs after luteinization of a large number of follicles. 2 OHSS appears to occur because of increased capillary permeability triggered by excessive release of one or more vasoactive substances secreted during maturation and luteinization of multiple follicles. One of the primary vasoactive substances is vascular endothelial growth factor (VEGF) of follicular origin. This peptide acts by promoting neovasculogenesis, and by increasing permeability of blood vessel walls. In addition, VEGF can alter cellular actin fibers, thereby compromising the integrity of tight cell junctions. VEGF levels correlate with both the presence and severity of OHSS. Because of the functional impairment of blood vessels not only within the ovary, a massive fluid shift occurs from the intravascular to the third compartment. This shift results in intravascular hypovolemia, concomitant with development of edema, ascites, and pleural and pericardial effusions. Cardiac, renal, pulmonary and liver function can be impaired. 2 Massive follicular luteinization is usually only observed in exogenous gonadotropin cycles following administration of hCG, or after administration of gonadotropin-releasing hormone agonist. Rarely, it occurs in women treated with clomiphene citrate. Clinical symptoms of OHSS usually appear 5 to 10 days following the first dose of the ovulatory trigger. 2 Mild OHSS can rarely develop following an endogenous LH surge. This has been described in case reports, particularly in women with polycystic ovarian syndrome or hypothyroidism. 3, 4 Severe, recurrent OHSS during pregnancy has been described in several reports. In some of these instances, the OHSS occurred because of a mutation in the serpentine region of the follicle stimulating hormone (FSH) receptor that resulted in a broadening of ligand specificity, thereby allowing stimulation by endogenous hCG. Persistent stimulation of the FSH receptor during pregnancy resulted in excessive follicular recruitment and subsequent ovarian hyperstimulation. [5] [6] [7] One case of spontaneous OHSS in pregnancy was attributed to a mutation in the hCG/LH receptor gene, which led to an exaggerated response to normal hCG levels. 8 Our patient's hCG level was markedly elevated at 430 525 IU l À1 . Usually in pregnancy, hCG rises soon after implantation, 8 to 10 days following conception. The hCG concentration typically doubles every 29 to 53 h during the first 30 days of a viable conception. Peak hCG levels are usually reached at 8 to 10 weeks of gestation. The range of normal is wide at 5000 to 150 000 IU l À1 . In the next 10 weeks, the hCG levels generally decline and reach a median concentration of 12 000 IU l À1 (range of normal is 2000 to 50 000 IU l À1 ). The hCG concentration then stays fairly constant from 20 weeks until term. 9 hCG levels are on average twice as high with fetal trisomy 21 compared with unaffected pregnancies. hCG is a placental secretory product. In the developing embryo, cytotrophoblasts comprise the inner trophoblastic layer, anchoring the chorion to the maternal endometrium. Mononuclear cytotrophoblasts, the stem cells in the chorionic villi, differentiate and fuse into multinucleated syncytiotrophoblasts. The syncytiotrophoblasts make up the outer trophoblastic layer and actively invade the uterine wall. Cells from the syncytiotrophoblast secrete progesterone and hCG. hCG maintains the corpus luteum until the luteal-placental shift in progesterone synthesis occurs. 10 There are several hypotheses regarding the increased levels of hCG in the setting of fetal trisomy 21. In 1999, Goshen 11 described a possible gene dosage effect. In general, hCG synthesis is limited by the rate of synthesis of its b-chain subunit. Goshen postulated that perhaps a transcriptional factor located on chromosome 21 interacts with the b 5 -promoter, upregulating b-chain formation. He theorized that the presence of an additional chromosome 21 in Down syndrome would further stimulate hCG production. 11 There is evidence that elevated hCG levels in Down syndrome could be explained by the immature cytotrophoblasts, which are prevalent in the aneuploid placenta. Placentae from trisomy 21 pregnancies contain an underdeveloped syncytiotrophoblast layer, with stromal edema, reduced vascularization, abnormal umbilical blood flow and an abundance of cytotrophoblasts. 12 Although in vivo expression of hCG is associated with formation of syncytiotrophoblasts, cytotrophoblasts express abundant amounts of hCG before the sixth week of pregnancy. At present, it is unclear which regulatory mechanisms control hCG production in the diverse trophoblast cell types. 13 However, in in vitro models, differentiation of cytotrophoblasts to syncytiotrophoblasts is hCG dependent. Low concentrations of hCG promote cellular aggregation and hCG receptor expression, whereas high doses of hCG have the opposite effect. 14 Higher concentrations of hCG could occur with trisomy 21 because cytotrophoblasts are too immature to form syncytia and to downregulate their own hormone synthesis. Alternatively, upregulation of hCG may result in suppression of cell fusion.
In this patient's case, elevated serum hCG levels likely resulting from fetal trisomy 21 were associated with mild OHSS. OHSS associated with fetal aneuploidy has not been previously described. As this association makes physiologic sense, it would be interesting to conduct further studies to determine how commonly this phenomenon occurs.
